Elevated C-Reactive Protein Linked with Poor Prognosis in Prostate Cancer
the Cancer Therapy Advisor take:
According to a new study published in the European Journal of Cancer, researchers have found that an elevated c-reactive protein level is associated with poor prognosis in treated patients with prostate cancer.
C-reactive protein is a biomarker of inflammation that has been associated with prognosis in numerous solid tumors.
For this study, researchers sought to investigate whether or not a c-reactive protein is associated with prognosis in patients with prostate cancer treated with radiation. Researchers enrolled 261 patients with prostate cancer who were treated with 3D-conformal radiotherapy and were followed for a median duration of 80 months.
Researchers determined that the optimal cut-off level for plasma c-reactive protein was 8.6mgl-1. Multivariate analyses showed that an elevated c-reactive protein level was linked with decreased cancer specific survival (HR = 4.31; 95% CI: 1.22 - 15.1; P = 0.023).
In addition, results showed an association between an elevated c-reactive protein level and decreased overall survival (HR = 3.24; 95% CI: 1.84 - 5.71; P < 0.001), and clinical disease-free survival (HR = 2.07; 95% CI: 1.02 - 4.17; P = 0.043).
The findings suggest that an elevated plasma c-reactive protein level of 8.6mgl-1 is associated with a poor prognosis, but additional studies are warranted to confirm the results.
An elevated c-reactive protein level is associated with poor prognosis in treated patients with prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma